Memory Pharmaceuticals Corporation

Dr. Reddy's Laboratories, Incorporated

Allelix Biopharmaceuticals Inc.

Nps Allelix Corporation

Other

Nps Pharmaceuticals, Inc.

Painceptor Pharma Corporation

Memory Pharmaceutical Corporation

F. Hoffmann-La Roche Ag

Ashok Tehim

Richard A Schumacher

Wenge Xie

Brian Herbert

Truc Minh Nguyen

Allen T Hopper

Carla Gauss

Jianguo Ma

Abdelmalik Slassi

Pradip Kumar Sasmal

Tao Xin

Louise G Edwards

Vidyadhar Madhav Paradkar

Shahadat Ahmed

Sumanas Rakhit

Ruiping Liu

Jian-Min Fu

Hans-Jurgen E Hess

Robert F Dunn

Mihaela Diana Danca

Vijay Potluri

Jalaj Arora

Yonghua Gai

Shawn Maddaford

Hang Zhang

Methvin Benjamin Isaac

Francisco Xavier Talamas

Sharada Shenvi Labadie

Erik Mikal Kuester

William F Brubaker

Ian Egle

Ish Khanna

Joan Marie Caroon

Prasanna M Dattatreya

Nanjegowda Jagadeesh Mavinahalli

Anne O'Brien

Axel Unterbeck

Michael De Vivo

Yajing Rong

Robert A Kirby

True Minh Nguyen

Elizabeth Doorly Graham

Ganesh Prabhu

Marahanakuli Prasanna Dattatreya

Nanjegowda Jagadeesh Mavinhalli

Chintakunta Vamseekrishna

William J Delaney

Richard Conticello

Thomas Hogberg

Vamsee Krishna Chintakunta

Jian-min Fu

Methvin Issac

Thomas E Renau

Qi Qiao

Mahaboobi Jaleel

Oystein Rist

Lisbeth Elster

Thomas Michael Frimurer

Lars-Ole Gerlach

Mark Phillip Arrington

William Frederick Brubaker, Jr

Xiannong Chen

Mike De Vivo

Hans-Jürgen Ernst Hess

Hans-J&uuml;rgen Ernst Hess

Zhaoqing Wang

Carla Maria Gauss

The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.

Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors

The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. wherein R, R, R, R, R, and Rare as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (&#x3ba;) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.

Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists

Substituted pyrazolo[1,5-A] pyridine as tropomyosin receptor kinase (TrK) inhibitors

The present application relates to a series of substituted imidazo[1,2-a]pyridine compounds of formula (I), pharmaceutically acceptable salts, pharmaceutically acceptable solvates or stereoisomers thereof, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.

Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors

The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts, wherein R, R, R, R, R, and Rare as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (&#x3ba;) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS. 

The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, R1s, R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (&#x3ba;) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS. 

Kappa opioid receptor agonists

The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds

Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the &#x3b1;7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof

Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

Growing community of inventors

Ridgewood, NJ, United States of America

Ashok Tehim